Progeria: A rare genetic premature ageing disorder

Indian Journal of Medical Research

Volumn 139, Issue MAY, 2014, Pages 667-674

  Sinha, Jitendra Kumar ^a   Ghosh, Shampa ^a   Raghunath, Manchala ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

Author keywords

Accelerated ageing; Clinical trial; Experimental models; Farnesylation; Hutchinson Gilford progeria syndrome; Lamin A; LMNA gene; Lonafarnib; Longevity

Indexed keywords

HYALURONIC ACID; LAMIN A; LONAFARNIB; TRANSCRIPTION FACTOR II; LMNA PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

AGING; CATARACT; GENE MUTATION; HUMAN; LEUKOPLAKIA; LIFE EXPECTANCY; NAIL DYSTROPHY; OSTEOPOROSIS; PHOTOSENSITIVITY; PROGERIA; REVIEW; SKIN PIGMENTATION; WEIGHT GAIN; CHILD; CLINICAL TRIAL (TOPIC); GENETICS; LONGEVITY; MUTATION; PATHOLOGY; PRENYLATION; RARE DISEASE;

AGING; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; LAMIN TYPE A; LONGEVITY; MUTATION; PIPERIDINES; PRENYLATION; PROGERIA; PYRIDINES; RARE DISEASES;

EID: 84903776671     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Kamenisch Y, Berneburg M. progeroid syndromes and UV-induced oxidative DNA damage. J investig dermatol Symp Proc 2009; 14: 8-14.
2. Progeria Research Foundation (pRF) webpage. Availablefrom: http://www.progeriaresearch.org/meet_the_kids.html, accessed on May 17, 2014.
3. Pereira S, Bourgeois P, Navarro C, Esteves-Vieira V, Cau DeSandre-Giovannoli A, et al. HGpS and related premature aging disorders: from genomic identification to the first therapeutic approaches. Mech ageing dev 2008; 129: 449-59.
4. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am jmed genet A 2006; 140: 2603-24.
5. Shalev SA, De Sandre-Giovannoli A, Shani AA, Levy N. Anassociation of Hutchinson-Gilford progeria and malignancy. Am A 2007; 143: 1821-6.
6. Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, Alisch R, et al. Positional cloning of the Werner's syndrome gene. Science 1996; 272: 258-62.
7. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423: 293-8.
8. Espandar R, Eraghi AS, Mardookhpour S. Simultaneousshoulder and hip dislocation in a 12-year-old girl with hutchinson-gilford progeria syndrome. Acta med Iran 2012; 50: 439-43.
9. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl j2008; 358: 592-604.
10. Rastogi R, Chander Mohan SM. progeria syndrome: a casereport. Indian orthop 2008; 42: 97-9.
11. Fukuchi K, Katsuya T, Sugimoto K, Kuremura M, Kim HD, Li L, et al. LMNA mutation in a 45 year old Japanese subject with Hutchinson-Gilford progeria syndrome. J med genet 2004; 41: e67.
12. Oshima J, Martin GM, Hisama FM. Werner Syndrome. In:pagon RA, Adam Mp, Ardinger HH, Bird TD, Dolan CR, Fong CT, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
13. Huang S, Lee L, Hanson NB, Lenaerts C, Hoehn H, Poot M, et al. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat 2006; 27: 558-67.
14. Satoh M, Imai M, Sugimoto M, Goto M, Furuichi Y. Prevalenceof Werner's syndrome heterozygotes in Japan. Lancet 1999; 353: 1766.
15. Cerimele D, Cottoni F, Scappaticci S, Rabbiosi G, BorroniG, Sanna E, et al. High prevalence of Werner's syndrome in Sardinia. Description of six patients and estimate of the gene frequency. Hum Genet 1982; 62: 25-30.
16. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011; 2011: 480-6.
17. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat genet 1998; 19: 32-8.
18. Kleijer WJ, Laugel V, Berneburg M, Nardo T, FawcettH, Gratchev A, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA repair (Amst) 2008; 7: 744-0.
19. Laugel V, Dalloz C, Durand M, Sauvanaud F, Kristensen U, Vincent MC, et al. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. Hum Mutat 2010; 31: 113-26.
20. Weidenheim KM, Dickson DW, Rapin I. Neuropathology ofCockayne syndrome: evidence for impaired development, premature aging, and neurodegeneration. Mech ageing dev 2009; 130: 619-36.
21. Cao H, Hegele RA. LMNA is mutated in Hutchinson-Gilfordprogeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J hum genet 2003; 48: 271-4.
22. McClintock D, Ratner D, Lokuge M, Owens DM, GordonLB, Collins FS, et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PloS One 2007; 2: e1269.
23. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 2005; 102: 10291-6.
24. Capell BC, Collins FS. Human laminopathies: nuclei gonegenetically awry. Nat rev Genet 2006; 7: 940-52.
25. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects inhuman aging. Science 2006; 312: 1059-63.
26. Jung HJ, Coffinier C, Choe Y, Beigneux AP, Davies BS, YangSH, et al. Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc Natl Acad Sci USA 2012; 109: E423-31.
27. Manju K, Muralikrishna B, Parnaik VK. Expression of disease-causing lamin A mutants impairs the formation of DNA repair foci. J cell sci 2006; 119 (Pt 13): 2704-14.
28. Scaffidi P, Misteli T. Reversal of the cellular phenotype inthe premature aging disease Hutchinson-Gilford progeria syndrome. Nat med 2005; 11: 440-5.
29. Raffaele Di Barletta M, Ricci E, Galluzzi G, Tonali P, Mora M, Morandi L, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000; 66: 1407-12.
30. Doh YJ, Kim HK, Jung ED, Choi SH, Kim JG, Kim BW, et al. Novel LMNA gene mutation in a patient with Atypical Werner's Syndrome. Korean J Intern Med 2009; 24: 68-72.
31. De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, Kassouri N, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70: 726-36.
32. Young SG, Fong LG, Michaelis S. prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J lipid res 2005; 46: 2531-58.
33. Yang SH, Qiao X, Fong LG, Young SG. Treatment with afarnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim biophys acta 2008; 1781: 36-9.
34. Chen CY, Chi YH, Mutalif RA, Starost MF, Myers TG, Anderson SA, et al. Accumulation of the inner nuclear envelope protein Sun1 is pathogenic in progeric and dystrophic laminopathies. Cell 2012; 149: 565-77.
35. Allsopp RC, Vaziri H, Patterson C, Goldstein S, YounglaiEV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10114-8.
36. Decker ML, Chavez E, Vulto I, Lansdorp PM. Telomere length in Hutchinson-Gilford progeria syndrome. Mech Ageing Dev 2009; 130: 377-83.
37. Aubert G, Lansdorp PM. Telomeres and aging. Physiol rev 2008; 88: 557-79.
38. Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, BhatN, Naqashima K, et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J cell Biol 1999; 147: 913-20.
39. Mounkes LC, Kozlov S, Hernandez L, Sullivan T, Stewart CL. A progeroid syndrome in mice is caused by defects in A-type lamins. Nature 2003; 423: 298-301.
40. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, RobinsonAR, Appeldoorn E, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006; 444: 1038-43.
41. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, KendallLV, et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci USA 2002; 99: 13049-54.
42. Pendás AM, Zhou Z, Cadiñanos J, Freije JM, Wang J, HultenbyK, et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat genet 2002; 31: 94-9.
43. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311: 1621-3.
44. Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J clin invest 2006; 116: 2115-21.
45. Marino G, Ugalde AP, Fernandez AF, Osorio FG, Fueyo A, Freije JM, et al. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. Proc Natl Acad Sci USA 2010; 107: 16268-73.
46. Russell SJ, Kahn CR. Endocrine regulation of ageing. Nat rev Mol cell biol 2007; 8: 681-91.
47. Meta M, Yang SH, Bergo MO, Fong LG, Young SG. proteinfarnesyltransferase inhibitors and progeria. Trends mol med 2006; 12: 480-7.
48. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, SchreiberKH, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci transl med 2012; 4: 144ra103.
49. Verstraeten VL, Ji JY, Cummings KS, Lee RT, LammerdingJ. Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilfordprogeria cells: effects of farnesyltransferase inhibitors. Aging cell 2008; 7: 383-93.
50. Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, MoulsonCL, et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 2005; 102: 12873-8.
51. Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, TavarezUL, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA 2008; 105: 15902-7.
52. Varela I, Pereira S, Ugalde AP, Navarro CL, SuárezMF, Cau P, et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat med 2008; 14: 767-72.
53. Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. In press: 2014.
54. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2012; 109: 16666-71.
55. Kieras FJ, Brown WT, Houck GE, Jr., Zebrower M. Elevationof urinary hyaluronic acid in Werner's syndrome and progeria. Biochem med metab biol 1986; 36: 276-82.
56. Zebrower M, Kieras FJ, Brown WT. urinary hyaluronic acidelevation in Hutchinson-Gilford progeria syndrome. Mech ageing dev 1986; 35: 39-46.
57. Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, et al. Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford progeria syndrome. Hum genet 2003; 113: 178-87.
58. Holzenberger M. The GH/IGF-I axis and longevity. Eur jendocrinol 2004; 151 (Suppl 1): S23-7.
59. Capell BC, Tlougan BE, Orlow SJ. From the rarest to the mostcommon: insights from progeroid syndromes into skin cancer and aging. J invest dermatol 2009; 129: 2340-50.
60. Sinha JK, Ghosh S, Swain U, Giridharan NV, Raghunath M. Increased macromolecular damage due to oxidative stress in the neocortex and hippocampus of WNIN/Ob, a novel rat model of premature aging. Neuroscience 2014; 269: 256-64.
61. Bandaru P, Rajkumar H, Nappanveettil G. Altered or impairedimmune response upon vaccination in WNIN/Ob rats. Vaccine 2011; 29: 3038-42.
62. Harishankar N, Vajreswari A, Giridharan NV. WNIN/GR-Ob-an insulin-resistant obese rat model from inbred WNIN strain. Indian J Med Res 2011; 134: 320-9.